Navigation Links
Mainz University Medical Center receives further DFG funding for cardiovascular research
Date:1/29/2013

The German Research Foundation (DFG) has again approved funding for the Department of Internal Medicine II of the Mainz University Medical Center to promote cardiovascular research for the second time within only a few weeks. The aim of the project currently being sponsored is to investigate the relationships between free radicals and disorders of the cardiovascular system. The team, led by biologist Dr. Swenja Krller-Schn and PD Dr. Eberhard Schulz, senior physician at the Department of Internal Medicine II of the Mainz University Medical Center, has a particular interest in how specific enzyme systems regulate vascular function. These significantly influence the formation of free radicals, inflammatory reactions, and vascularization. It is thus hoped that the results of this theoretical research will make it possible to diagnose vascular diseases at an even earlier stage and to intervene with targeted treatment to prevent related complications, such as myocardial infarction. The researchers intend to spend the approximately EUR 210,000 funding granted over the next two years on human resources and consumables.

In this project, the research team will be studying to what extent molecules that control the energy consumption of cells also have a long-term effect on vascular function. "This correlation seems to make sense because when energy reserves decrease, cells need to be supplied with substrates in the blood stream and, for this purpose, adequate dilation of the blood vessels is necessary. However, the correlations between the mechanisms involved in this process have still not been sufficiently explained," stated Krller-Schn and Schulz.

The successful acquisition of third-party funds is also attributable to the strategy adopted by the University Medical Center, namely that of establishing specialized research units. Within this context, the research team led by Dr. Swenja Krller-Schn and PD Dr. Eberhard Schulz has managed to form partnerships that are important for the future of translational medicine. "We are pleased that the German Research Foundation has recognized our achievements and has decided to sponsor us. The work of the Research Unit Vascular Prevention and the establishment of the Center for Thrombosis and Hemostasis (CTH) with the support of the Mainz Heart Foundation have created an environment in which applications have a greater chance of success," said Prof. Dr. Thomas Mnzel, Coordinator of the Research Unit Vascular Prevention at Mainz University Medical Center.


'/>"/>

Contact: Swenja Krller-Schn
swenja.kroeller-schoen@gmx.de
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Related medicine news :

1. DFG funds new Collaborative Research Center at the Mainz University Medical Center
2. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
3. Scientists at the Mainz University Medical Center gain new insights into Taspase1 function
4. University of Tennessee researcher finds first time could predict sexual satisfaction
5. Lavender Languages Conference celebrates 20 years at American University
6. Spring Classes for Wexford University’s Online Doctoral Degree in Applied Sport Psychology Begin April 1
7. To Meet Growing Demand for Sports Psychology Experts, Wexford University Offers Master’s Degree in Applied Sport Psychology: Classes Begin April 1
8. Wexford University’s Master’s Degree in Nutrition and Exercises Prepares Weight Management Coaches and Consultants: Spring Quarter Launches April 1
9. Wayne State University researcher to evaluate success of text message diabetes intervention
10. University of Southern Mississippi Department of Marine Science Researches Marine Algae as Alternative Fuel Source
11. McGill University Launches a Major New Study on HPV Prevention Using Divine 9 Personal Lubricants with Carragel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: